[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:acute-leukemia":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":117,"states":122},"Acute Leukemia",17,15,[8,16,23,30,36,42,48,54,61,67,73,79,85,91,97,103,110],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05537896","Prospective Evaluation of Xerava Prophylaxis in Hematological Malignancy Patients With Prolonged Neutropenia",[12],"Phase 2","RECRUITING","2026-08-26T02:15:46.655893Z","2026-05-05T02:43:28.217829Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT04811560","A Phase 1\u002F2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:16:02.918558Z","2026-05-05T02:43:27.311203Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06376162","Ziftomenib in Combination With Chemotherapy for Children With Relapsed\u002FRefractory Acute Leukemia",[27],"Phase 1","2026-08-26T02:19:02.550788Z","2026-05-05T02:43:27.310236Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07493538","MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases",[12],"2026-08-26T02:17:09.131534Z","2026-05-05T02:43:28.880222Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06466395","A Phase I Study of Hyper-CVAD In Combination With Venetoclax In Pediatric Patients With Relapsed or Refractory Acute Leukemias That Are of the Lymphoid Lineage Including Bi-Phenotypic or Undifferentiated Leukemias",[27],"2026-08-26T02:19:08.862440Z","2026-05-05T02:43:28.289024Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT04187105","BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)",[12],"2026-08-26T02:17:44.240289Z","2026-05-05T02:43:27.748653Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT07249346","Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FRuxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation",[12],"2026-08-26T02:17:56.243868Z","2026-05-05T02:35:31.751095Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":59,"content_modified":60},"NCT06615050","A Study of Tacrolimus\u002FMethotrexate\u002FRuxolitinib Versus Post-Transplant Cyclophosphamide\u002FTacrolimus\u002FMycophenolate Mofetil in Non-Myeloablative\u002FReduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)",[58],"Phase 3","2026-08-26T02:16:04.914942Z","2026-07-05T05:32:16.764159Z",{"nct_id":62,"title":63,"phases":64,"status":13,"updated_at":65,"content_modified":66},"NCT07565220","Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies",[27],"2026-08-26T02:16:16.995720Z","2026-05-13T02:55:06.728889Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT05554068","Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients",[12],"2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.020712Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06229912","A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX Genes",[12],"2026-08-26T02:19:10.436356Z","2026-05-05T02:43:26.712984Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT02677064","Identify Barriers to Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed and Relapsed Acute Leukemia",[],"2026-08-26T02:18:00.873391Z","2026-07-30T01:46:14.456283Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":89,"content_modified":90},"NCT03680677","Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies",[],"2026-08-26T02:18:39.640967Z","2026-05-13T02:55:06.175358Z",{"nct_id":92,"title":93,"phases":94,"status":13,"updated_at":95,"content_modified":96},"NCT03050268","Familial Investigations of Childhood Cancer Predisposition",[],"2026-08-26T02:17:18.747857Z","2026-05-13T02:55:06.107926Z",{"nct_id":98,"title":99,"phases":100,"status":13,"updated_at":101,"content_modified":102},"NCT06907797","Tools for Reducing Inequity in Acute Leukemia (TRIAL): Beta Testing",[],"2026-08-26T02:18:36.226508Z","2026-05-05T02:43:28.983417Z",{"nct_id":104,"title":105,"phases":106,"status":107,"updated_at":108,"content_modified":109},"NCT01728402","Pathogenesis of Hematologic Malignancies",[],"ENROLLING_BY_INVITATION","2026-08-26T02:16:54.876240Z","2026-06-16T05:54:07.945845Z",{"nct_id":111,"title":112,"phases":113,"status":114,"updated_at":115,"content_modified":116},"NCT06367959","Health Benefits of Writing Therapy Among Asian American Cancer Survivors",[],"ACTIVE_NOT_RECRUITING","2026-08-03T02:27:16.454962Z","2026-05-05T02:43:27.073616Z",[118],{"biomarker":119,"count":120,"slug":121},"NUP98 Gene",3,"nup98-gene",[123,127,130,134,138,141,144,147,150,153],{"state":124,"count":125,"slug":126},"Pennsylvania",6,"pennsylvania",{"state":128,"count":125,"slug":129},"Texas","texas",{"state":131,"count":132,"slug":133},"New York",5,"new-york",{"state":135,"count":136,"slug":137},"Illinois",4,"illinois",{"state":139,"count":136,"slug":140},"Massachusetts","massachusetts",{"state":142,"count":136,"slug":143},"Tennessee","tennessee",{"state":145,"count":120,"slug":146},"California","california",{"state":148,"count":120,"slug":149},"Ohio","ohio",{"state":151,"count":120,"slug":152},"Oregon","oregon",{"state":154,"count":120,"slug":155},"Washington","washington"]